OTCs stronger for Taisho in first quarter
This article was originally published in Scrip
Executive Summary
Taisho saw its mainstay over-the-counter products rebound in the first quarter to June 30th, when net sales from self-medication operations rose by 11% to ¥38.6 billion ($358.9 million). Prescription sales were 4% higher at ¥23.2 billion, but were held back by a 7% year-on-year fall for top product Clarith (clarithromycin) to ¥5.7 billion following the general reimbursement price cut in April. Group net profit for the quarter was 28% higher at ¥7.7 billion, boosting earnings per share by the same margin to ¥25.87. Helped by cost cutting, the operating figure jumped by 42% to ¥11.6 billion.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.